Opportunistic Treatment of Hepatitis C Infection Among Hospitalised People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomised Trial

Midgard, Håvard; Malme, Kristian Braathen; Pihl, Charlotte Meinich; Berg-Pedersen, Riikka Mari; Tanum, Lars; Klundby, Ingvild; Haug, Anne; Tveter, Ida; Bjørnestad, Ronny; Olsen, Inge Christoffer; Finbråten, Ane‐Kristine; Dalgård, Olav

doi:10.2139/ssrn.4293865

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OPPORTUNI-C (ClinicalTrials.gov NCT04220645) was a pragmatic, open-label, multicenter, stepped wedge cluster randomized trial conducted between 1 October 2019 and 31 December 2021 in departments of internal medicine, addiction medicine, and psychiatry at three hospitals in Oslo, Norway [36]. The study enrolled 200 participants, 98 during intervention conditions (immediate treatment) and 102 during control conditions (standard of care outpatient treatment).…”

Section: Study Participantsmentioning

confidence: 99%

“…Baseline data, including sex, age, housing status, injecting drug use, OAT status, and stage of liver disease, was collected as part of the clinical trial [36]. Follow-up data were collected between 1 July 2022 and 8 August 2023.…”

Section: Data Collectionmentioning

confidence: 99%

“…Follow-up data were collected between 1 July 2022 and 8 August 2023. Data on DAA dispensations from the pharmacy were extracted retrospectively by reviewing the electronic patient files as previously described [36].…”

Section: Data Collectionmentioning

confidence: 99%

“…OPPORTUNI-C was a cluster randomized trial among hospitalized PWID demonstrating the superiority of opportunistic HCV treatment in terms of treatment completion and time to treatment initiation [36]. The study also documented SVR, but within a very limited time frame.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial

Malme,

Stene-Johansen,

Klundby

et al. 2024

Viruses

Self Cite

View full text Add to dashboard Cite

Treatment of hepatitis C among people who inject drugs (PWID) may be complicated by loss to follow-up and reinfection. We aimed to evaluate sustained virologic response (SVR) and reinfection, and to validate complete pharmacy dispensation as a proxy for cure among PWID enrolled in a trial of opportunistic HCV treatment. Data were obtained by reviewing the electronic patient files and supplemented by outreach HCV RNA testing. Reinfection was defined based on clinical, behavioral, and virological data. Intention to treat SVR ≥ 4 within 2 years after enrolment was accomplished by 59 of 98 (60% [95% CI 50–70]) during intervention conditions (opportunistic treatment) and by 57 of 102 (56% [95% CI 46–66]) during control conditions (outpatient treatment). The time to end of treatment response (ETR) or SVR ≥ 4 was shorter among intervention participants (HR 1.55 [1.08–2.22]; p = 0.016). Of participants with complete dispensation, 132 of 145 (91%) achieved ETR or SVR > 4 (OR 12.7 [95% CI 4.3–37.8]; p < 0.001). Four cases of reinfection were identified (incidence 3.8/100 PY [95% CI 1.0–9.7]). Although SVR was similar, the time to virologic cure was shorter among intervention participants. Complete dispensation is a valid correlate for cure among individuals at risk of loss to follow-up. Reinfection following successful treatment remains a concern.

show abstract

Section: Study Participantsmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial

Malme,

Stene-Johansen,

Klundby

et al. 2024

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…Forskere fra Akershus universitetssykehus, Oslo universitetssykehus og Lovisenberg Diakonale Sykehus publiserte nylig en randomisert kontrollert studie i tidsskriftet Clinical Infectious Diseases (1). I studien undersøkte man effekten av en ny behandlingsmodell med umiddelbar diagnostikk og behandling av hepatitt C hos pasienter innlagt i indremedisinske, rusmedisinske og psykiatriske sykehusavdelinger.…”

unclassified

Rask behandling av hepatitt C gir best resultater

Sørensen

2024

Tidsskriftet

View full text Add to dashboard Cite

Umiddelbar behandling av hepatitt C-infeksjon er mer effektivt enn en tradisjonell henvisningsbasert praksis. Fra venstre: Håvard Midgard (førsteforfatter), Olav Dalgard (sisteforfatter), Kristian Braathen Malme, Ane-Kristine Finbråten. Foto: Johan Stenseth Til tross for store fremskritt i behandlingen av pasienter med hepatitt Cinfeksjon, ligger mange land etter skjema for å oppnå WHOs mål om eliminasjon av hepatitt C innen 2030. Dette skyldes blant annet behandlingsmodeller som ikke er tilpasset de mest marginaliserte pasientene, saerlig rusmiddelbrukere.

show abstract

Opportunistic Treatment of Hepatitis C Infection Among Hospitalised People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomised Trial

Cited by 2 publications

References 0 publications

Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial

Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial

Rask behandling av hepatitt C gir best resultater

Contact Info

Product

Resources

About